Where to Get Testosterone Shots: A Practical Guide for Women

Why Women Ask About Testosterone Shots

Testosterone is not a "male hormone." It is the most abundant biologically active sex hormone in your body across your entire reproductive life, and levels begin declining in your late 20s, reaching roughly half their peak value by the time you enter perimenopause. Low testosterone in women is associated with fatigue, reduced libido, loss of muscle mass, and mood changes. Many women arrive at this question after a provider dismisses their symptoms or after reading about testosterone replacement therapy (TRT) in a context written almost entirely for men.

This guide is written specifically for you. The dosing, the physiology, the risks, and the places you go to get care are all different when you are a woman.

How Female Testosterone Physiology Differs From Male Physiology

Your baseline levels are already much lower

In women, total testosterone runs approximately 15 to 70 ng/dL, compared to 300 to 1,000 ng/dL in men. That tenfold difference is not a gap to close. It is a biological reality that shapes every dosing decision. An injection dose that restores normal male levels would push a woman into a supraphysiologic, androgenic state that causes acne, clitoral enlargement, voice deepening, and irreversible body-hair changes.

The menstrual cycle changes your levels daily

During the follicular phase your testosterone is at its monthly low. It spikes periovulatorily, sometimes by 30 to 40 percent, coinciding with increased sexual interest around ovulation. Laboratories draw blood on day 8 to 10 of your cycle for the most reproducible baseline reading. If your provider does not ask what cycle day you are on, that is a red flag.

SHBG is your key variable

Sex hormone-binding globulin (SHBG) binds testosterone and makes it biologically inactive. Oral estrogen, oral contraceptive pills, thyroid disease, and liver disease all raise SHBG, lowering your free (active) testosterone even when total testosterone looks normal. SHBG must be measured alongside total testosterone to calculate free testosterone accurately. Women on oral contraceptives often have suppressed free testosterone and high SHBG, a combination that can cause low libido independent of any other diagnosis.

Perimenopause and menopause change the picture significantly

Estradiol falls sharply at menopause. Testosterone follows a more gradual decline but does not disappear. By age 45 to 55, many women have testosterone levels in the lower quartile of the premenopausal reference range. After surgical menopause (bilateral oophorectomy), the drop is acute and often severe because the ovaries contribute roughly 25 percent of circulating testosterone directly.

Who This Is Right For (and Who Should Not Use It)

Testosterone therapy in women has its strongest evidence base for a specific indication: hypoactive sexual desire disorder (HSDD) in postmenopausal women. The 2019 Menopause Society (NAMS) Position Statement is direct on this point, supporting testosterone use for HSDD after excluding other causes such as relationship distress, depression, and medication side effects.

Women for whom testosterone may be appropriate

• Postmenopausal women (natural or surgical) with confirmed HSDD after ruling out other causes
• Perimenopausal women with declining libido and documented low free testosterone after cycle-appropriate testing
• Women with premature ovarian insufficiency (POI) or post-oophorectomy who have symptomatic androgen insufficiency
• Women with PCOS who paradoxically have low free testosterone (due to elevated SHBG from insulin resistance treatment) and symptomatic low androgen function

Women for whom testosterone is not appropriate

• Pregnant women. Full stop. Testosterone is teratogenic to female fetuses (see pregnancy section below).
• Women with androgen-sensitive cancers or those at high risk
• Women with uncontrolled polycythemia or high hematocrit at baseline
• Women with active liver disease
• Women who have not had adequate evaluation of other causes of their symptoms, such as thyroid dysfunction, iron-deficiency anemia, or depression

Where to Get Testosterone Shots as a Woman

Most women seeking testosterone injections are navigating a system that was not designed with them in mind. The FDA has approved no injectable testosterone product specifically for women in the United States. Every prescription is off-label. That creates a practical access problem: not all providers are comfortable prescribing off-label hormones, and many primary care physicians are not current on the evidence. Here is where you actually go.

OB-GYNs and Reproductive Endocrinologists

Your OB-GYN is often the best first call, particularly if they have a menopause or hormone subspecialty. ACOG supports individualized hormone therapy discussion for symptomatic women, and many OB-GYNs are familiar with off-label testosterone use for HSDD and perimenopause symptoms. Reproductive endocrinologists are especially well-suited to manage testosterone in the context of PCOS, POI, or fertility planning.

What to ask when you call: "Do you prescribe off-label testosterone for women with HSDD or low androgen symptoms? Do you monitor free testosterone and SHBG?"

NAMS-Certified Menopause Practitioners

The Menopause Society certifies clinicians who have demonstrated competency in menopause care. A NAMS-certified provider is more likely than a general internist to be current on the 2019 testosterone position statement, to know how to dose for women, and to monitor appropriately. This is the single most targeted specialist referral for postmenopausal women.

Women's-Health Nurse Practitioners

NPs with a women's-health or menopause focus routinely prescribe off-label hormones in states where their scope of practice allows independent prescribing. A WH-NP who has additional training in hormone therapy can order the right labs, interpret results in the context of your cycle or menopausal status, and manage dose titration over time.

Telehealth Platforms Specializing in Women's Hormonal Health

Several telehealth companies now focus specifically on women's hormonal health and offer testosterone prescribing alongside estrogen and progesterone when indicated. The advantages are access and convenience. The risks are variable provider quality and less consistent follow-up lab monitoring. If you use a telehealth service, confirm that:

1. The prescribing clinician has specific training in women's hormonal health (not just a general TRT clinic that also sees women).
2. The platform will order and review follow-up labs at three to six months, not just at baseline.
3. The compounding pharmacy they use is PCAB-accredited or operates under 503B outsourcing facility status.

What to Avoid

Avoid testosterone clinics whose marketing is aimed at men and who offer women the same injections and dosing protocols. A clinic prescribing testosterone cypionate at 100 mg/week to a woman is not following evidence-based female dosing. The Global Consensus Position Statement on testosterone use in women (published in the Journal of Clinical Endocrinology and Metabolism, 2019, with endorsement from The Menopause Society, Endocrine Society, ISSWSH, and RCOG) explicitly states that women should be maintained within the physiologic female reference range, not dosed to male levels.

What Injectable Testosterone Actually Looks Like for Women

Injectable testosterone is almost never the first-line route for women. The 2019 Global Consensus Statement prefers transdermal delivery (cream or gel) because it allows fine-grained dose control and avoids the peaks and troughs of injection schedules. Transdermal testosterone at 5 to 10 mg/day delivers roughly 300 to 500 mcg of absorbed testosterone daily, keeping levels in the physiologic female range.

When injections are used, they are almost always compounded testosterone cypionate or enanthate at very low doses:

• Typical injectable dose for women: 5 to 10 mg per week (compared to 100 to 200 mg/week in men)
• Route: subcutaneous (not intramuscular), using a 27- to 29-gauge needle into the abdomen or lateral thigh
• Frequency: weekly, to reduce the hormonal peak that occurs with longer intervals

Weekly subcutaneous micro-dosing is a method some compounding-pharmacy-prescribing physicians use to mimic the steadier delivery of a transdermal product while giving women who do not absorb creams well a viable alternative. This is not studied in large randomized controlled trials specifically; the evidence base for injections in women is largely extrapolated from the transdermal literature.

The APHRODITE and ADORE Trials

The best-quality evidence for testosterone in women comes from randomized controlled trials of transdermal testosterone patches and gels, not injections. The APHRODITE trial (2008) randomized 814 naturally menopausal women to 300 mcg/day testosterone patch versus placebo and showed a significant increase in satisfying sexual events at 52 weeks. The ADORE trial examined testosterone in estrogen-replete postmenopausal women and found similar benefit. Injectable testosterone in women has not been studied in equivalently powered female-specific trials, which is an evidence gap your provider should acknowledge.

Monitoring: What Labs You Need and When

Monitoring testosterone therapy in women is not optional. Supraphysiologic androgen levels cause irreversible virilizing effects. The Endocrine Society and The Menopause Society both recommend checking levels at three to six months after starting, then every six to twelve months once stable.

Labs to request at every monitoring visit:

| Lab | Why It Matters | |---|---| | Total testosterone | Baseline and therapy level | | Free testosterone (calculated or equilibrium dialysis) | Most clinically relevant measure | | SHBG | Affects free testosterone interpretation | | Hematocrit / hemoglobin | Testosterone raises red cell mass | | Lipid panel | Androgens may lower HDL at supraphysiologic doses | | Liver function | Relevant if using oral formulations |

Target free testosterone during therapy: the upper limit of the normal female reference range for your laboratory. Do not aim for male reference ranges.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

This section is not a formality. Testosterone is teratogenic, and this risk is real for any woman who still has ovarian function.

Pregnancy: Contraindicated

Testosterone is classified as FDA Pregnancy Category X. Animal and human data consistently show that testosterone exposure during pregnancy causes virilization of a female fetus, including clitoral enlargement, labioscrotal fusion, and ambiguous genitalia. These effects are dose-dependent but can occur even at lower doses used therapeutically. If you are using testosterone and become pregnant, stop immediately and contact your OB-GYN that same day.

Premenopausal women must use reliable contraception

If you are in your reproductive years, perimenopausal but still cycling, or have any chance of ovulation, reliable non-hormonal or progestin-only contraception is required throughout testosterone therapy. Testosterone does not reliably suppress ovulation. Combined oral contraceptive pills are not ideal alongside testosterone because they raise SHBG, which reduces free testosterone and can undermine the therapeutic effect.

Good contraceptive options to discuss with your provider:

• Copper IUD (non-hormonal, highly effective)
• Progestin-only IUD (levonorgestrel; raises SHBG less than oral estrogen-containing pills)
• Barrier methods used consistently

Lactation

Testosterone is excreted into breast milk. The extent of infant exposure and clinical significance are not well characterized in human studies, and current guidance from the Global Consensus Statement advises against testosterone therapy during breastfeeding. If you are postpartum and breastfeeding, defer testosterone initiation until after weaning and discuss the timing with your provider.

Women With PCOS: A Different Conversation

PCOS is the most common endocrine disorder in women of reproductive age, affecting approximately 8 to 13% of women globally. The majority of women with PCOS already have elevated androgens. For most of them, adding testosterone therapy would be inappropriate and potentially harmful.

However, a subset of women with PCOS, particularly those who have been treated with high-dose metformin or those using combined oral contraceptives long-term, develop suppressed free testosterone secondary to elevated SHBG. These women can present with symptoms that look like androgen insufficiency even against a background diagnosis of androgen excess. This requires careful specialist evaluation, and decisions about testosterone in this group should only be made by a reproductive endocrinologist or OB-GYN with specific PCOS expertise, after detailed androgen profiling.

Women with PCOS who are seeking testosterone therapy are not candidates for a general TRT clinic. Their hormonal picture requires individualized interpretation.

Female Pattern Hair Loss and Testosterone: A Nuanced Risk

Androgenic alopecia (female pattern hair loss, FPHL) affects approximately 40% of women by age 50. Exogenous testosterone can worsen FPHL in genetically susceptible women. Before starting testosterone therapy, your provider should ask about your personal and family history of hair thinning. If you have significant FPHL, the risk of acceleration is real and should be weighed against the expected benefit.

If you proceed with testosterone despite FPHL risk, a dermatologist familiar with hormonal hair loss should be part of your care team, and your dose should be kept at the lowest effective level.

The HSDD Question: What the Evidence Actually Supports

Hypoactive sexual desire disorder affects an estimated 10% of premenopausal women and up to 30% of postmenopausal women. Testosterone is the only treatment with consistent randomized controlled trial evidence for HSDD in postmenopausal women. The 2019 Global Consensus Statement reviewed 36 RCTs and concluded that testosterone therapy improves sexual function, including desire, arousal, pleasure, and orgasm, in postmenopausal women. The evidence in premenopausal women is less developed.

HSDD is a clinical diagnosis, not a lab value. A low testosterone level alone does not diagnose HSDD, and a normal testosterone does not exclude it. Treatment requires clinical assessment, not just a number on a lab slip.

Questions to Ask Any Provider Before Starting

Before you agree to a prescription, confirm these points with your provider:

1. "What is my free testosterone and SHBG, and what do those numbers mean given where I am in my cycle or menopausal status?"
2. "What dose are you proposing, and how does it compare to the physiologic female range?"
3. "What route of administration are you recommending and why, given the evidence for women specifically?"
4. "How will we monitor for virilizing side effects, and what is the plan if they occur?"
5. "What contraception is required if I still have ovarian function?"
6. "How long do you typically trial testosterone before reassessing benefit?"

A provider who cannot answer these questions in the context of female physiology is not the right provider for this therapy.